Share on StockTwits
 

DexCom (NASDAQ:DXCM) CFO Jess Roper unloaded 8,000 shares of the company’s stock on the open market in a transaction that occurred on Tuesday, January 21st. The stock was sold at an average price of $37.38, for a total value of $299,040.00. Following the sale, the chief financial officer now directly owns 65,808 shares in the company, valued at approximately $2,459,903. The sale was disclosed in a document filed with the SEC, which can be accessed through this link.

A number of analysts have recently weighed in on DXCM shares. Analysts at Benchmark Co. raised their price target on shares of DexCom from $40.00 to $44.00 in a research note to investors on Tuesday, January 14th. They now have a “buy” rating on the stock. Separately, analysts at Raymond James reiterated a “buy” rating on shares of DexCom in a research note to investors on Thursday, November 7th. They now have a $34.00 price target on the stock. Finally, analysts at JPMorgan Chase & Co. reiterated a “buy” rating on shares of DexCom in a research note to investors on Thursday, November 7th. They now have a $32.00 price target on the stock. Six research analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. The stock has a consensus rating of “Hold” and an average target price of $30.30.

DexCom (NASDAQ:DXCM) traded down 1.27% on Wednesday, hitting $37.20. The stock had a trading volume of 445,287 shares. DexCom has a 52 week low of $14.05 and a 52 week high of $38.20. The stock’s 50-day moving average is $35.25 and its 200-day moving average is $29.47. The company’s market cap is $2.670 billion.

DexCom (NASDAQ:DXCM) last announced its earnings results on Wednesday, November 6th. The company reported ($0.09) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.13) by $0.04. The company had revenue of $42.90 million for the quarter, compared to the consensus estimate of $35.90 million. During the same quarter last year, the company posted ($0.25) earnings per share. DexCom’s revenue was up 85.7% compared to the same quarter last year. Analysts expect that DexCom will post $-0.46 EPS for the current fiscal year.

DexCom, Inc (NASDAQ:DXCM) is a medical device company focused on the design, development and commercialization of continuous glucose monitoring systems for ambulatory use by people with diabetes and for use by healthcare providers in the hospital for the treatment of both diabetic and non-diabetic patients.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.